Molecular Determinants and Other Factors to Guide Selection of Patients for Hepatic Resection of Metastatic Colorectal Cancer

被引:0
作者
Thomas M. Diehl
Daniel E. Abbott
机构
[1] University of Wisconsin,Department of Surgery
[2] University of Wisconsin,Department of Surgery, Division of Surgical Oncology
来源
Current Treatment Options in Oncology | 2021年 / 22卷
关键词
Colorectal cancer; Liver metastasis; Hepatectomy; CRLM; KRAS; BRAF;
D O I
暂无
中图分类号
学科分类号
摘要
Treatment for metastatic colorectal cancer (CRC) has changed significantly over the last few decades as cytotoxic and targeted chemotherapies have evolved and resection of (technically feasible) colorectal liver metastases (CRLM) has become standard of care for eligible patients. Overall, survival for metastatic CRC has considerably improved, but recurrences are common. Numerous clinical risk scores have been suggested to guide patient selection for CRLM resection, but none perfectly predict outcomes; therefore, a personalized approach to metastatic CRC treatment using genetic profiles for risk stratification and prognostication is a critically important advancement. All patients with suspected metastatic CRC should undergo genetic testing for common oncogene mutations (e.g., KRAS, BRAF, and NRAS) in addition to a triphasic CT scan of the chest, abdomen, and pelvis; if hepatectomy may be entertained and there is concern about the future liver remnant (FLR), liver volumetrics should also be performed. MRI and PET are useful adjuncts for cases in which diagnosis or extent of disease is unclear. The decision to operate should be individualized and based on each patient’s condition, tumor biology, and technical resectability. Genetic profiles should be used to inform multidisciplinary meetings surrounding topics of chemotherapy and surgical resection, as well as patient discussions concerning the risks and benefits of surgery. In the end, most patients with technically resectable colorectal cancers and adequate cardiopulmonary fitness benefit from surgical resection, as it remains the only chance of long-term survival.
引用
收藏
相关论文
共 230 条
  • [1] Tosi F(2017)Effect of KRAS and BRAF mutations on survival of metastatic colorectal cancer after liver resection: a systematic review and meta-analysis Clin Colorectal Cancer 16 e153-e163
  • [2] Magni E(2019)Colorectal liver metastases: an update on multidisciplinary approach World J Hepatol 11 150-172
  • [3] Amatu A(1999)Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases Ann Surg 230 309-318
  • [4] Mauri G(2010)Prognostic scores for colorectal liver metastasis: clinically important or an academic exercise? HPB (Oxford) 12 227-238
  • [5] Bencardino K(2018)Clinical risk scores in the current era of neoadjuvant chemotherapy for colorectal liver metastases ANZ J Surg 88 E16-E20
  • [6] Truini M(2020)Coaltered Ras/B-raf and TP53 is associated with extremes of survivorship and distinct patterns of metastasis in patients with metastatic colorectal cancer Clin Cancer Res 26 1077-1085
  • [7] Chow FC-L(2020)Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver-only and lung-only metastases Oncol Lett 20 2119-2130
  • [8] Chok KS-H(2015)Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases Br J Surg 102 1175-1183
  • [9] Fong Y(2015)Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases Ann Surg Oncol 22 4158-4165
  • [10] Fortner J(2021)Association of RAS mutation location and oncologic outcomes after resection of colorectal liver metastases Ann Surg Oncol 28 817-825